Literature DB >> 10900130

The formation of stable fatty acid substrate complexes in prostaglandin H(2) synthase-1.

M G Malkowski1, M J Theisen, A Scharmen, R M Garavito.   

Abstract

We have developed a protocol to purify apo-ovine (o) prostaglandin endoperoxide H(2) synthase-1 (PGHS-1) to homogeneity from ram seminal vesicles. The resulting apo enzyme can then be reconstituted with Co(3+)-protoporphyrin IX instead of Fe(3+)-protoporphyrin IX to produce a native-like, but functionally inert, enzyme suitable for the production of enzyme:fatty acid substrate complexes for biophysical characterization. Co(3+)-protoporphyrin IX reconstituted oPGHS-1 (Co(3+)-oPGHS-1) displays a Soret band at 426 nm that shifts to 406 nm upon reduction. This behavior is similar to that of cobalt-reconstituted horseradish peroxidase and myoglobin and suggests, along with resonance Raman spectroscopy, that the Co(3+)-protoporphyrin IX group is one in a six-coordinate, cobalt(III) state. However, Co(3+)-oPGHS-1 does not display cyclooxygenase or peroxidase activity, nor does the enzyme produce prostaglandin products when incubated with [1-(14)C]arachidonic acid. The cocrystallization of Co(3+)-oPGHS-1 and the substrate arachidonic acid (AA) has been achieved using sodium citrate as the precipitant in the presence of the nonionic detergent N-octyl-beta-d-glucopyranoside. Crystals are hexagonal, belonging to the space group P6(5)22, with cell dimensions of a = b = 181.69 A and c = 103.74 A, and a monomer in the asymmetric unit. GC-MS analysis of dissolved crystals indicates that unoxidized AA is bound within the crystals. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10900130     DOI: 10.1006/abbi.2000.1906

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  8 in total

1.  Pleiotropic mechanisms facilitated by resveratrol and its metabolites.

Authors:  Barbara Calamini; Kiira Ratia; Michael G Malkowski; Muriel Cuendet; John M Pezzuto; Bernard D Santarsiero; Andrew D Mesecar
Journal:  Biochem J       Date:  2010-07-15       Impact factor: 3.857

2.  The structural basis of endocannabinoid oxygenation by cyclooxygenase-2.

Authors:  Alex J Vecchio; Michael G Malkowski
Journal:  J Biol Chem       Date:  2011-04-13       Impact factor: 5.157

3.  Structural basis of fatty acid substrate binding to cyclooxygenase-2.

Authors:  Alex J Vecchio; Danielle M Simmons; Michael G Malkowski
Journal:  J Biol Chem       Date:  2010-05-12       Impact factor: 5.157

4.  Physical evidence for substrate binding in preventing cyclooxygenase inactivation under nitrative stress.

Authors:  Ruba S Deeb; Cynthia Cheung; Tal Nuriel; Brian D Lamon; Rita K Upmacis; Steven S Gross; David P Hajjar
Journal:  J Am Chem Soc       Date:  2010-03-24       Impact factor: 15.419

5.  Inducible nitric oxide synthase mediates prostaglandin h2 synthase nitration and suppresses eicosanoid production.

Authors:  Ruba S Deeb; Hao Shen; Caryn Gamss; Tatyana Gavrilova; Barbara D Summers; Rosemary Kraemer; Gang Hao; Steven S Gross; Muriel Lainé; Nobuyo Maeda; David P Hajjar; Rita K Upmacis
Journal:  Am J Pathol       Date:  2006-01       Impact factor: 4.307

6.  Fatty Acid Binding to the Allosteric Subunit of Cyclooxygenase-2 Relieves a Tonic Inhibition of the Catalytic Subunit.

Authors:  Liang Dong; Chong Yuan; Benjamin J Orlando; Michael G Malkowski; William L Smith
Journal:  J Biol Chem       Date:  2016-10-18       Impact factor: 5.157

7.  The crystal structure of α-Dioxygenase provides insight into diversity in the cyclooxygenase-peroxidase superfamily.

Authors:  Christopher C Goulah; Guangyu Zhu; Mary Koszelak-Rosenblum; Michael G Malkowski
Journal:  Biochemistry       Date:  2013-02-14       Impact factor: 3.162

8.  Acetylation of prostaglandin H2 synthases by aspirin is inhibited by redox cycling of the peroxidase.

Authors:  Manju Bala; Cindy N Chin; Asha T Logan; Taneem Amin; Lawrence J Marnett; Olivier Boutaud; John A Oates
Journal:  Biochem Pharmacol       Date:  2007-12-27       Impact factor: 5.858

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.